Chemotherapy and targeted therapies have significantly improved the prognosis of
oncology patients. However, these antineoplastic treatments may also induce adverse …

The advent of iPSCs has brought about a significant transformation in stem cell research,
opening up promising avenues for advancing cancer treatment. The formation of cancer is a …

Trastuzumab (TZM) is commonly used for target therapy in breast cancer patients with high
HER2 although the cardiotoxicity restricts its clinical usage. DNA damage and ferroptosis …

Nanotechnology has emerged as a promising approach for the targeted delivery of
therapeutic agents while improving their efficacy and safety. As a result, nanomaterial …

Mitochondrial dysfunction may lead to cardiomyocyte death in trastuzumab (TZM)-induced
cardiotoxicity. Accordingly, this study was designed to evaluate the mitochondrial protective …

Clinical use of trastuzumab (TZM), has been widely associated with increased incidence of
cardiotoxicity. Ocimum gratissimum Linn. is a household medicinal plant popularly used for …

One of the biggest challenges in neuro-oncology is understanding the complexity of central
nervous system tumors, such as gliomas, in order to develop suitable therapeutics …

There are significant considerations about the prevention of cardiotoxicity caused by
trastuzumab therapy in patients with breast cancer, leading to discontinuation. Recently …

Improvements in cancer care have led to an exponential increase in cancer survival. This is
particularly the case for breast cancer, where 5-year survival in Australia exceeds 90 …

Background Elevated pre-treatment baseline inflammation has been associated with cancer
therapy-related cardiac dysfunction (CTRCD) in patients with breast cancer. Monocyte-to …